Satoshi Tanaka
Osaka, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 64 publications
Renewed Response to Pembrolizumab After Salvage Radiotherapy for Oligoprogression in Advanced NSCLC: A Case Report.
Journal: Respirology case reports
Published: April 10, 2026
Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Journal: Journal for immunotherapy of cancer
Published: March 16, 2026
Systemic immune profiling uncovers divergent mechanisms and predictive biomarkers of response to combination immunotherapies in hepatocellular carcinoma.
Journal: Journal for immunotherapy of cancer
Published: March 16, 2026
Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non-Squamous Non-Small Cell Lung Cancer: A Multicenter Retrospective Study.
Journal: Thoracic cancer
Published: January 31, 2026
Lymphocyte-to-Monocyte Ratio as a Practical Biomarker for Immunotherapy Response in Hepatocellular Carcinoma.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: November 22, 2025
Monocyte-derived IL-1β predicts and promotes HBsAg decline in chronic hepatitis B patients under nucleoside analogue therapy.
Journal: Hepatology communications
Published: October 31, 2025
Proteomic Analysis of Serum Extracellular Vesicles Revealed Fibulin-3 as a Novel Predictive Biomarker for Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: October 16, 2025
Endobronchial Watanabe Spigot for Acute Empyema With Bronchopleural Fistula: A Case Series.
Journal: Respirology case reports
Published: October 07, 2025
Multicenter retrospective study of selpercatinib treatment for advanced or recurrent RET fusion-positive non-small cell lung cancer in Japan.
Journal: Investigational new drugs
Published: August 30, 2025
NRF2-COX2-PGE2 axis drives immune cold tumors and predicts resistance to combination immunotherapy in hepatocellular carcinoma.
Journal: Hepatology (Baltimore, Md.)
Published: August 21, 2025
Clinical Outcomes of First-Line Pembrolizumab Monotherapy in Advanced NSCLC With PD-L1 Tumor Proportion Score of 1% to 49%: A Retrospective Multicenter Study.
Journal: JTO clinical and research reports
Published: August 18, 2025
Long-term survival comparison of first-line pembrolizumab versus pembrolizumab plus chemotherapy for patients with advanced non-small cell lung cancer: A multicenter propensity-matched cohort study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: August 12, 2025
Last Updated: 09/26/2026